Nautilus Biotechnology (NAUT) Scheduled to Post Quarterly Earnings on Tuesday

Nautilus Biotechnology (NASDAQ:NAUT) is scheduled to announce its earnings results before the market opens on Tuesday, April 30th. Analysts expect the company to announce earnings of ($0.16) per share for the quarter. Individual that wish to listen to the company’s earnings conference call can do so using this link.

Nautilus Biotechnology (NASDAQ:NAUT) last released its quarterly earnings data on Wednesday, February 28th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.16) by $0.02. During the same period in the prior year, the firm earned ($0.11) earnings per share. On average, analysts expect Nautilus Biotechnology to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Nautilus Biotechnology Trading Down 1.6 %

NAUT stock opened at $2.42 on Tuesday. The stock has a market capitalization of $302.74 million, a PE ratio of -4.65 and a beta of 1.20. Nautilus Biotechnology has a 12-month low of $2.16 and a 12-month high of $4.65. The stock’s 50 day simple moving average is $2.69 and its 200 day simple moving average is $2.82.

Insider Activity at Nautilus Biotechnology

In other Nautilus Biotechnology news, CEO Sujal M. Patel acquired 12,044 shares of the stock in a transaction that occurred on Monday, March 11th. The shares were acquired at an average cost of $2.84 per share, with a total value of $34,204.96. Following the transaction, the chief executive officer now owns 10,064,488 shares of the company’s stock, valued at approximately $28,583,145.92. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In other Nautilus Biotechnology news, CEO Sujal M. Patel acquired 12,044 shares of the stock in a transaction that occurred on Monday, March 11th. The shares were acquired at an average cost of $2.84 per share, with a total value of $34,204.96. Following the transaction, the chief executive officer now owns 10,064,488 shares of the company’s stock, valued at approximately $28,583,145.92. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Sujal M. Patel bought 18,854 shares of the firm’s stock in a transaction on Thursday, March 7th. The shares were bought at an average price of $2.89 per share, with a total value of $54,488.06. Following the completion of the purchase, the chief executive officer now owns 10,050,014 shares in the company, valued at approximately $29,044,540.46. The disclosure for this purchase can be found here. In the last three months, insiders have acquired 38,303 shares of company stock valued at $108,316. 42.50% of the stock is owned by corporate insiders.

About Nautilus Biotechnology

Nautilus Biotechnology, Inc, a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis.